[{"Assets_0_Q3_USD":1547476000.0,"CommonStockSharesOutstanding_0_Q3_shares":17563.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-21997000.0,"NetIncomeLoss_1_Q3_USD":-15251000.0,"NetIncomeLoss_3_Q3_USD":636667000.0,"StockholdersEquity_0_Q3_USD":850581000.0,"EarningsPerShareBasic_1_Q3_USD":-0.81,"EarningsPerShareBasic_3_Q3_USD":32.51,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":18770000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":19586000.0,"Ticker":"LGND","CIK":"886163","name":"LIGAND PHARMACEUTICALS INC","OfficialName":"Ligand Pharmaceuticals Incorporated Common Stock","form":"10-Q","period":"20190930","fy":"2019.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1738856427.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20191108"}]